Why the study?
Does recombinant human IGF-I alter fasting concentrations of glucose, C-peptide, IGF-I, and IGFBPs in obese type II diabetics?
Population
6 obese type II diabetics
Design
Case_series
Follow-up
4 days
Authors
Loading...
May modulate IGF bioavailability in obese T2D; hypothesis-generating case report requiring controlled validation.
Does recombinant human IGF-I alter fasting concentrations of glucose, C-peptide, IGF-I, and IGFBPs in obese type II diabetics?
In obese type II diabetics, short-term administration of IGF-I alters the distribution of IGF-binding proteins, increasing IGFBP-1 and -2 while decreasing IGFBP-3.
Young et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: